• Defining Small-Molecule Binding Sites on GCGR: Insights from

  2026-04-20

  This study integrates crystallography and molecular simulations to map the binding sites of small-molecule antagonists on the glucagon receptor (GCGR), with a focus on MK 0893. The findings clarify the structural determinants of antagonist selectivity and lay groundwork for more targeted type 2 diabetes therapies.

• Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis

  2026-04-20

  This study establishes a prognostic model for hepatocellular carcinoma (HCC) based on ferroptosis-related genes and identifies atorvastatin as a promising agent to induce ferroptosis in HCC cells. The findings offer new avenues for prognosis prediction and potential therapeutic intervention in HCC, with direct validation through in vitro and in vivo experiments.

• SU 5402: Deep Mechanistic Insights for RTK Inhibition in Onc

  2026-04-19

  Explore SU 5402, a potent receptor tyrosine kinase inhibitor, as a tool for dissecting oncogenic signaling. This article uniquely connects advanced pathway analysis with practical assay design, offering new depth for cancer biology and multiple myeloma research.

• AMD-070 Hydrochloride: Applied CXCR4 Antagonist Workflows

  2026-04-18

  Mavorixafor hydrochloride (AMD-070 hydrochloride) is redefining CXCR4 antagonist use in cell migration and anti-HIV research with robust solubility and high specificity. This guide translates key experimental parameters into actionable workflows and troubleshooting strategies, leveraging APExBIO’s reagent reliability to maximize reproducibility and impact.

• 2-NBDG Empowers Advanced Glucose Metabolism Assays

  2026-04-17

  2-NBDG, a fluorescent glucose analog, revolutionizes real-time quantification of cellular glucose uptake in live-cell and disease models. Its compatibility with cutting-edge techniques—flow cytometry, fluorescence microscopy, and microplate assays—offers researchers unmatched sensitivity and workflow flexibility.

• 7-Ethyl-10-hydroxycamptothecin: Reliable Workflows for Viabi

  2026-04-16

  This article addresses common laboratory challenges in cell viability and cytotoxicity assays, focusing on how 7-Ethyl-10-hydroxycamptothecin (SKU N2133) delivers reproducible, data-backed solutions for advanced colon cancer research. With an evidence-based approach, we explore real-world experimental scenarios, protocol optimization, and product selection—highlighting the strengths of APExBIO’s reagent for sensitive and robust outcomes.

• P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via Ca2+/CaM

  2026-04-15

  Li et al. (2025) demonstrate that P2RX1 overexpression enhances mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) by modulating intracellular calcium signaling and suppressing the PI3K/Akt pathway. These mechanistic insights reveal P2RX1 as a potential therapeutic target and support the use of precision apoptosis detection strategies in translational leukemia research.

• Annexin-V Detection of Cardiomyocyte Death in Murine I/R Mod

  2026-04-14

  This study introduces recombinant human annexin-V as a highly sensitive in situ marker for early cardiomyocyte death in mouse models of myocardial ischemia and reperfusion (I/R). By characterizing the temporal dynamics of cell death and comparing annexin-V labeling to traditional DNA fragmentation assays, the research provides a refined experimental framework for evaluating cell death–blocking interventions in cardiovascular research.

• ZNF706 as a Diagnostic and Therapeutic Target in HCC: Eviden

  2026-04-13

  This study identifies Zinc Finger Protein 706 (ZNF706) as a robust biomarker and potential therapeutic target in hepatocellular carcinoma (HCC), showing significant overexpression in tumor tissue and strong diagnostic value. The findings are supported by a combination of large-scale bioinformatics, in vitro functional assays, and rigorous validation, highlighting the translational potential for future clinical and biotechnological applications.

• Lipid Scrambling, Ferroptosis, and Tumor Immunity: New Mecha

  2026-04-12

  Yang et al. reveal that TMEM16F-mediated lipid scrambling suppresses ferroptosis at the plasma membrane, and its inhibition enhances tumor immune rejection, especially when combined with PD-1 blockade. This research uncovers a previously uncharacterized execution-phase event in ferroptosis, suggesting new avenues for cancer immunotherapy and membrane biology studies.

• D-Luciferin Sodium Salt: Optimizing Macrophage Imaging in Ad

  2026-04-12

  Explore how D-Luciferin sodium salt enables next-generation bioluminescent imaging for engineered macrophage assays in cancer immunotherapy. This article offers a unique perspective on substrate selection, methodological innovations, and translational impact, grounded in the latest research.

• Hexa His Tag Peptide: Precision Tool for 6X His Protein Puri

  2026-04-11

  Hexa His tag peptide streamlines the competitive elution and purification of His-tagged proteins, eliminating antibody contamination and enhancing reproducibility. Discover step-by-step protocols, advanced applications, and troubleshooting strategies that optimize your immunoprecipitation and protein interaction studies.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Advanced Lab Appl

  2026-04-11

  Digoxin, a gold-standard Na+/K+ ATPase pump inhibitor, enables robust cardiac and virology research through precise modulation of cell physiology. This guide translates recent pharmacokinetic insights and experimental best practices into actionable protocols, empowering researchers to achieve reproducible, high-impact results in both cardiovascular and antiviral workflows.

• Vernakalant Hydrochloride in Translational Research: Mech...

  2026-04-10

  Translational researchers face the persistent challenge of rapidly and safely converting atrial fibrillation (AF) to sinus rhythm, balancing efficacy, tolerability, and mechanistic specificity. Vernakalant Hydrochloride (RSD1235), an atrial-selective antiarrhythmic agent, delivers a unique ion channel blockade profile that has redefined the therapeutic landscape for short-duration AF. This thought-leadership article synthesizes the biological rationale, experimental and clinical validation, competitive differentiation, and translational strategies—offering a strategic framework for those seeking to navigate the next phase of antiarrhythmic drug development and application.

• Troglitazone: Selective PPARγ/α Agonist for Type 2 Diabet...

  2026-04-09

  Troglitazone is a dual PPARγ/α agonist with validated effects on lipid and glucose metabolism. It serves as a reference tool for type 2 diabetes research and exhibits apoptosis-inducing activity in renal carcinoma models. This article provides atomic, verifiable insights for experimental design and corrects common misconceptions about Troglitazone's research applications.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page